Birthday Celebrations Gone Wrong When A Hydrogen Balloon Exploded, Leaving The 33-year-Old Birthday Girl With First And Second Degree Burns

Updated Feb 26, 2025 | 11:00 PM IST

SummaryThe right way to treat a burn depends on its depth and how much of the body it covers. While minor, superficial burns can be managed at home, deeper or larger burns may need medical attention. For Giang Pham, whose hydrogen balloon exploded, it will take around around 6 months to fully recover.
Giang Pham's birthday celebrations gone wrong with hydrogen balloon exploding on her face and hand

Credits: Instagram

Birthdays are exciting for everyone. There's celebration, a cake, and balloons. But what if it goes wrong? This is what happened with Giang Pham, from Vietnam, who was celebrating her 33rd birthday on February 14, when a hydrogen balloon in her hand touched the flame from the candle on the cake and exploded on her face.

This incident was also captured on camera. The footage clearly shows how the balloon blew up as soon as it touched the flame. Her friends were shocked and can be heard gasping in the background as they saw this.

In the days following the incident, she also shared photos on her Instagram showing her bandaged face, and revealed the first-degree burns on her hand and second-degree burns on her face. However, the good news was that her vision was unaffected, though for her face to recover, it would take months.

She is now also warning others about the risks of using highly inflammable hydrogen balloons. The other alternative could be a helium balloon, which you could fly higher and they remain on the ceiling.

Health Update

She revealed that her doctor estimated up to six months for her skin to recover. She would still have to go to the hospital for dressing and treatment. Another such case happened with a woman named Tine from Australia, when on her son's 7th birthday, the balloon exploded and "shook her house". Her son was burned in the forearm.

Such incidents happen because decorators want to save the cost by replacing helium with hydrogen, which is highly inflammable.

In Healing

Giang shared that she experienced second-degree burn on her face and first-degree burn on her hands. As per John Hopkins Medicine, first degree burns affect only the epidermis, or the outer layer of skin. The burn site becomes red, painful, dry, however, there are no blisters. A mild sunburn could be an example of such a burn. This is also called superficial burns.

Whereas, second degree burns involve the epidermis and part of the dermis layer of the skin. The burn site appears red, blistered and could also be swollen and painful. This is also known as partial thickness burn.

Then comes the third degree burns, also known as full thickness burn. This destroys the epidermis and dermis and could also damage the underlying bones, muscles, and tendons. However, when the bones and muscles are burned, it could be referred to as a fourth degree burn. The burn sit appears white or charred and there is no feeling in the area since the nerve endings are destroyed.

How burns are treated?

The right way to treat a burn depends on its depth and how much of the body it covers. While minor, superficial burns can be managed at home, deeper or larger burns may need medical attention. Keep these essential guidelines in mind:

Do:

  • Remove the source of the burn immediately – For example, take off clothing soaked in hot liquid to prevent further damage.
  • Run cool water over the burn – This helps soothe the skin, except in cases of certain chemical burns.
  • Keep the burn clean and protected – Cover it with a clean, non-stick bandage when possible.
  • Seek medical help – If the burn is deeper than a superficial layer, larger than your hand, or full-thickness, see a doctor.

Don’t:

  • Use home remedies like bleach or butter – These can make the burn worse.
  • Apply ointments or creams on deep burns – They can trap heat and worsen the injury.
  • Put ice on the burn – It can cause more damage to the skin.
  • Pop blisters – This increases the risk of infection.

Knowing these simple steps can make a big difference in burn care and healing.

End of Article

President Donald Trump Remains In Excellent Health, Says White House

Updated May 30, 2026 | 06:00 PM IST

SummaryPresident Trump remains in excellent health, demonstrating strong cardiac, pulmonary, neurological, and overall physical function, according to Dr. Sean Barbabella, physician to the president.
President Donald Trump Remains In Excellent Health, Says White House

Credit: AP

Putting an end to speculation over US President Donald Trump’s health, the White House has announced that the 79-year-old is in “excellent health”.

Trump underwent his annual medical examination at Walter Reed National Military Medical Center on May 26.

"President Trump remains in excellent health, demonstrating strong cardiac, pulmonary, neurological, and overall physical function," Dr. Sean Barbabella, physician to the president, wrote in the memo, released late Friday evening.

He added that Trump is "fully fit to carry out all duties of the Commander-in-Chief and Head of State."

Trump’s health became a major subject of discussion after photographs at times showed swollen ankles, bruised hands, and a blotchy neck. He has been spotted several times with slurred speech and naps during official meetings.

Shortly after the examination, Trump said that "everything checked out perfectly."

Trump, who turns 80 in June, is the oldest person to assume the presidency. He frequently portrays himself as more energetic and fitter than Joe Biden, his Democratic predecessor, who left office last year at age 82 after facing questions about his fitness for the job.

Barbabella described the assessment as a “comprehensive preventive evaluation,” which included a thorough review of all diagnostic studies and laboratory testing conducted over the past year.

It also included “consultations with twenty-two specialty providers from multiple academic institutions. All aspects of the assessment were performed in accordance with US Preventive Services Task Force recommendations,” he said in the memo.

Also read: ‘Sea Or See?’ Donald Trump's Remark Sparks Fresh Cognitive Health Speculation

Diagnostic Summary

The President’s diagnostic summary showed:

  • Vision is normal.
  • Hearing is intact, and teeth are in very good condition.
  • The thyroid and lymph nodes are normal. An ultrasound of the carotid arteries showed normal results.
  • The lungs and chest demonstrated no abnormalities.
  • Coronary CT angiography demonstrated no arterial obstruction or structural abnormalities of the heart or major vessels.
  • An echocardiogram showed no abnormalities. Cardiac function is normal, and circulation to the extremities remains intact.
  • Gastrointestinal/abdominal and genitourinary examinations were normal.
  • Slight lower leg swelling was noted, with improvement from last year.

Barbabella further said that the medical test also evaluated his hands and “revealed ecchymosis (bruising), consistent with minor soft tissue irritation related to frequent handshaking in the setting of aspirin use for cardiovascular prevention". He added that it is “a common and benign effect of aspirin therapy.”

The examination also found no “suspicious lesions or concerning growths.”

Neurological Health

Read More: Was Trump Sleeping During Oval Office Event? White House Reacts

The President's neurological condition was significantly targeted, with many doctors pointing out that he's suffering from dementia. But the test results, authorized by the President for public release, revealed him to be in “normal mental status".

Further, it showed that his "cranial nerves are intact", and he also has "normal motor strength, sensation, reflexes, gait, and balance.”

Trump also completed the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) screenings for depression and anxiety, both of which were "normal".

Cognitive function, assessed using the Montreal Cognitive Assessment (MoCA), was also within normal limits, with a score of 30 out of 30.

Lab Results

Comprehensive laboratory evaluation, including a complete blood count, comprehensive metabolic panel, coagulation profile, D-dimer, B-type natriuretic peptide, and cardiac biomarkers, remained within normal limits, Barbabella said.

End of Article

India Makes Significant Progress In Maternal Care, Nutrition And Child Immunization: NFHS-6

Updated May 29, 2026 | 07:00 PM IST

SummaryNFHS-6 reported encouraging progress in child nutrition indicators, with a significant decline in stunting, severe wasting, and underweight prevalence among children under five years. Coverage of major vaccines such as rotavirus and measles also improved significantly.
India Makes Significant Progress In Maternal Care, Nutrition And Child Immunization: NFHS-6

Credit: PIB

India’s Ministry of Health and Family Welfare (MoHFW) has released the National Family Health Survey-6 (NFHS-6), showing major improvements in maternal healthcare, nutrition, immunization, and family planning across the country.

The nationwide survey, which covered nearly 6.79 lakh households across 715 districts, highlighted stronger healthcare access and improved outcomes for women and children in the country.

Key Findings of NFHS-6

The NFHS-6 was conducted during 2023-24 by MoHFW with the International Institute for Population Sciences (IIPS), Mumbai as the nodal agency.

Maternal Care

NFHS-6 recorded notable gains in maternal and child healthcare services nationwide. Nearly 96 per cent of pregnant women received antenatal care (ANC), while mothers receiving ANC during the first trimester increased from 70.0 per cent to 76.2 per cent.

The percentage of mothers receiving at least four ANC visits also rose from 58.5 per cent to 65.2 per cent, reflecting improved continuity of maternal healthcare services.

Institutional deliveries increased from 88.6 per cent to 90.6 per cent, bringing India closer to universal institutional delivery coverage.

Maternal nutrition indicators also improved significantly. Women consuming iron folic acid supplements for 100 days or more during pregnancy increased from 44.1 per cent to 54.9 per cent. Those consuming supplements for 180 days or more rose from 26.0 per cent to 37.8 per cent.

India Makes Significant Progress In Maternal Care, Nutrition And Child Immunization: NFHS-6

Family Planning

India’s Total Fertility Rate (TFR) remained stable at 2.0, while the Contraceptive Prevalence Rate (CPR) increased from 66.7 per cent to 69.1 per cent.

The findings reflect improved access to family planning services and the continued impact of government programs, including Mission Parivar Vikas.

Child Immunization

India also recorded progress towards universal immunization coverage. Full vaccination coverage among children aged 12-23 months increased from 83.8 per cent to 87.1 per cent based on vaccination cards.

More than 95 per cent of children received vaccinations through public health facilities, highlighting continued trust in the public healthcare system.

Coverage of major vaccines improved significantly. Rotavirus vaccination coverage surged from 36.4 per cent to 85.4 per cent, while coverage of the second dose of measles-containing vaccine increased from 58.6 per cent to 71.8 per cent.

The survey also found improvement in child health indicators. Symptoms of acute respiratory infection (ARI) among children declined from 2.8 per cent to 1.9 per cent, while severe diarrhea prevalence fell to 0.5 per cent.

The gains were attributed to stronger last-mile healthcare delivery, improved cold chain systems, digital tracking through U-WIN, and active community participation under the Universal Immunization Program.

Also read: Ebola: Inside India’s RT-PCR Tests For The Bundibugyo Strain| Explained

Child Nutrition Outcomes

NFHS-6 also reported encouraging progress in child nutrition indicators. More than 95 per cent of children under six months were breastfed during the survey period. The percentage of children breastfed within one hour of birth increased from 41.8 per cent to 50.1 per cent.

Stunting among children under five years declined sharply from 35.5 per cent to 29.3 per cent, indicating improvement in long-term nutritional outcomes.

Severe wasting declined from 7.7 per cent to 5.2 per cent, while underweight prevalence among children under five registered a marginal decline from 32.1 per cent to 31.8 per cent.

Infant and young child feeding practices also improved. Children aged 6-8 months receiving solid or semi-solid food along with breastmilk increased from 45.9 per cent to 59.5 per cent.

End of Article

Bundibugyo Ebola Outbreak: WHO Identifies Experimental Treatments, Vaccines

Updated May 29, 2026 | 05:00 PM IST

Summary​The WHO recommends that all identified products should be used exclusively within clinical trials to generate robust data and ensure safe, ethical, and effective research.
Bundibugyo Ebola Outbreak: WHO Identifies Experimental Treatments, Vaccines

Credit: iStock

Amid the ongoing deadly Ebola outbreak, the World Health Organization (WHO) has identified experimental treatments and vaccine candidates for the Bundibugyo strain, which currently has no approved vaccine or antiviral treatment.

The global health agency convened several expert and advisory groups and recommended prioritizing treatment of Bundibugyo cases with:

  • Mapp Biopharmaceutical's MBP134
  • Regeneron’s maftivimab
  • Gilead Sciences’ antiviral remdesivir

In addition, the WHO also advised evaluating combination therapy using a monoclonal antibody together with remdesivir.

The advisory groups recommended that all identified products should be used exclusively within clinical trials to generate robust data and ensure safe, ethical, and effective research.

Preventive Therapies, Vaccine Candidates

Beyond treatment, the WHO also proposed therapies for the prevention of Bundibugyo cases.

  • For post-exposure prophylaxis among contacts of confirmed and probable cases, the oral antiviral obeldesivir was identified as a priority candidate.

  • The expert groups also identified the single-dose rVSV Bundibugyo vaccine, being developed by the International AIDS Vaccine Initiative (IAVI), as the most promising vaccine candidate.
Also read: Ebola: Inside India’s RT-PCR Tests For The Bundibugyo Strain| Explained

The development of the vaccine is expected to take approximately 7–9 months before it can be assessed through clinical trials for its ability to prevent Bundibugyo disease (BDV).

  • Another vaccine candidate, ChAdOx1 Bundibugyo — being developed by Oxford University and the Serum Institute of India — could potentially become available within 2–3 months for efficacy assessment through a clinical trial. However, additional animal data are still required to support and confirm further prioritization.
Experts noted that a single-dose approach for this candidate could be suitable for contacts of Ebola cases, while a two-dose strategy may be considered for high-risk but unexposed populations such as healthcare workers and frontline responders.

  • The experts also reviewed the potential role of Merck's Ervebo, the only licensed Ebola vaccine currently available.
Ervebo is approved for use during outbreaks caused by the most common Ebola virus species in Africa from the Orthoebolavirus family. However, it is not licensed for the prevention of Bundibugyo disease, and evidence regarding cross-protection against other Ebola virus species remains limited and inconclusive.

The WHO stated that Ervebo should not be used outside carefully designed research settings so that its performance against Bundibugyo disease can be properly assessed.

Meanwhile, Regeneron said in a statement that supplies of maftivimab are already available in the Democratic Republic of Congo, if the WHO decides to utilize the treatment immediately or include it as part of additional studies.

Read More: Donald Trump Says Health Check-Up Went 'Perfectly'

Russian Vaccine For New Strain

Meanwhile, Russia has claimed that its scientists have developed a novel vaccine against a new Ebola strain.

According to Russian Health Minister Murashko, "the vaccine may also protect against the rare Bundibugyo strain linked to the current outbreak in the DR Congo".

It is because the "genetic similarity between this virus variant and the vaccine strain is about 60-70%," Alexander Gintsburg, scientific director of the Gamaleya National Center of Epidemiology and Microbiology, was quoted as saying GxP News.

The rare Bundibugyo strain has so far caused over 900 cases and more than 200 deaths in the Democratic Republic of the Congo and Uganda.

End of Article